Media Center

News Releases

KYTHERA® Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
August 18, 2015

Submission supported by four pivotal Phase III trials conducted in Europe and North America with more than 1,500 patients  Westlake Village, Calif., U.S., August 18, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today it has submitted a Marketing Authorization Application (MAA) in the European Union (EU), seeking approval for ATX-101 (deoxycholic acid) injection as…

KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update
August 6, 2015

Company Executing on Commercial Launch of KYBELLA™ (deoxycholic acid) Injection Westlake Village, Calif., Aug. 6, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the second quarter of 2015, and provided an update on recent developments. “We are pleased with the market interest and excitement related to the launch of KYBELLA™, the first…

Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration
August 5, 2015

NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration DUBLIN, IRELAND and WESTLAKE VILLAGE, CALIF. – August 5, 2015 – Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc….

Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA
July 27, 2015

NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA DUBLIN, IRELAND and WESTLAKE VILLAGE, CALIF. – July 27, 2015 – Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc….

KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA™, A Submental Contouring Injectable Drug
July 27, 2015

Recently Launched as KYBELLA™ in the U.S., BELKYRA™ deoxycholic acid Injection Improves Appearance and Profile of Moderate to Severe Submental Fullness or “Double Chin” Westlake Village, Calif., July 27, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it has received authorization from Health Canada to market BELKYRA™ “for improvement in the appearance of moderate…

KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA™ – First FDA-Approved Injectable Treatment for “Double Chin” – Through KYBELLA™ Trained Physicians
June 19, 2015

Westlake Village, Calif., June 19, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the U.S. availability of KYBELLA™ (deoxycholic acid) injection, the first and only FDA-approved non-surgical treatment for reduction of submental fullness, a common yet under-treated aesthetic condition also known as “double chin.” KYBELLA™ was approved in April by the U.S. Food and…

Allergan to Acquire KYTHERA Biopharmaceuticals
June 17, 2015

NEWS RELEASE CONTACTS: Allergan: Investors:Lisa DeFrancesco (862) 261-7152 Media:David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan to Acquire KYTHERA Biopharmaceuticals – Complements Allergan’s Existing Position in Facial Aesthetics – – Lead Product KYBELLATM the First and Only Approved Non-surgical Treatment for Reduction of Submental Fullness – – Enhances…

KYTHERA Biopharmaceuticals To Present at the Goldman Sachs 36th Annual Global Healthcare Conference
June 3, 2015

Westlake Village, Calif., June 3, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that John Smither, chief financial officer, will present at the Goldman Sachs 36th Annual Global Healthcare Conference. Event:      Goldman Sachs 36th Annual Global Healthcare Conference Date:       Tuesday, June 9, 2015 Time:       2:00 p.m. PT A live…

KYTHERA Biopharmaceuticals To Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 8, 2015

Westlake Village, Calif., May 8, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference. Event:      Bank of America Merrill Lynch 2015 Health Care Conference Date:       Thursday, May 14, 2015 Time:…

KYTHERA Biopharmaceuticals Releases First Quarter 2015 Operating Results and Progress Update
May 7, 2015

Company Well Positioned for Commercial Launch of KYBELLA™ (deoxycholic acid) Injection Westlake Village, Calif., May 7, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the first quarter of 2015, and provided an update on recent accomplishments. “KYTHERA recently achieved our most significant milestone to date, that of receiving FDA approval of KYBELLA™,…